Buchumschlag

Editorial: Redefining Decompensation in Cirrhosis—More Than an Academic Playground? Authors' Reply

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Lucie Simonis, Lorenz Balcar, Georg Kramer, Thomas Reiberger, Georg Semmler
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2025
Schlagworte:	Alimentary Pharmacology & Therapeutics
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Refining Prognosis in Cirrhosis Patients With Ascites: Impact of Acute vs. Non‐Acute Decompensation
von: Lucie Simonis, et al.
Veröffentlicht: (2025)

Letter: Zinc and Selenium—Potential Biomarkers for Chronic Liver Disease? Authors' Reply
von: Nina Dominik, et al.
Veröffentlicht: (2024)

Editorial: Diabetes Management in Cirrhosis—The Window of Opportunity Before Decompensation. Authors' Reply
von: Mary Yue Wang, et al.
Veröffentlicht: (2026)

Letter: Trajectories of Hepatic Function Markers Enable Early Prediction of Hepatic Recompensation
von: Benedikt Silvester Hofer, et al.
Veröffentlicht: (2026)

Editorial: Caught in the Middle—Exploring the Grey Zone Between Decompensated and Recompensated HBV ‐Related Cirrhosis. Authors' Reply
von: Bingqiong Wang, et al.
Veröffentlicht: (2025)

Letter on ‘Clinical Features of Portal Hypertension and Their Prognostic Implications in Patients With Autoimmune Hepatitis’: Authors' Reply
von: Lukas Burghart, et al.
Veröffentlicht: (2026)

Letter: Attempted Validation of Villin‐1 as a Gut Barrier Marker in Decompensated Cirrhosis—Potential Confounding by Tubular Injury and Aetiology. Authors' Reply
von: David Tornai, et al.
Veröffentlicht: (2026)

Prevalence and prognostic value of zinc and selenium deficiency in advanced chronic liver disease
von: Nina Dominik, et al.
Veröffentlicht: (2024)

Editorial: Diabetes Management in Cirrhosis—The Window of Opportunity Before Decompensation
von: Thanawin Pramotedham, et al.
Veröffentlicht: (2026)

Indocyanine Green Clearance Correlates With Biomarkers Reflecting Key Disease‐Driving Mechanisms in Advanced Chronic Liver Disease and Predicts Acute‐on‐Chronic Liver Failure and Death
von: Mathias Jachs, et al.
Veröffentlicht: (2025)

Editorial: Statin Therapy in Cirrhosis: More Than Just Lipid‐Lowering
von: Emily Stephenson, et al.
Veröffentlicht: (2026)

Biomarkers of Extracellular Matrix Remodelling Are Linked to Severity and Outcome of Advanced Chronic Liver Disease
von: Benedikt Simbrunner, et al.
Veröffentlicht: (2025)

Editorial: ABID‐LSM–A Promising Model for Predicting Decompensation Risk in MASLD Cirrhosis
von: Eduardo Vilar‐Gomez, et al.
Veröffentlicht: (2025)

Insulin‐like growth factor‐1 in cirrhosis is linked to hepatic dysfunction and fibrogenesis and predicts liver‐related mortality
von: Lukas Hartl, et al.
Veröffentlicht: (2024)

Editorial: Caught in the Middle—Exploring the Grey Zone Between Decompensated and Recompensated HBV ‐Related Cirrhosis
von: Stephanie Tsai, et al.
Veröffentlicht: (2025)

Unstable Recompensation: An Intermediate Subtype in Patients With HBV ‐Related Decompensated Cirrhosis
von: Shuai Xia, et al.
Veröffentlicht: (2025)

Editorial: Navigating the Beta‐Blocker Dilemma in Advanced Liver Cirrhosis—When Is the Right Time to Discontinue? Authors' Reply
von: Ting Wang, et al.
Veröffentlicht: (2024)

Editorial: Decoding Gut Failure in Cirrhosis—Villin‐1 and the Emergence of a Seventh Organ Failure. Authors' Reply
von: David Tornai, et al.
Veröffentlicht: (2026)

Letter: Amino Acid Imbalance and Mortality in Cirrhosis—Interpretation and Methodological Considerations. Authors' Reply
von: Yuki Utakata, et al.
Veröffentlicht: (2026)

Editorial: Redefining Safety in Post‐Liver Transplant IBD —Why Therapeutic Effectiveness Is the Ultimate Shield. Authors' Reply
von: Simone Chin, et al.
Veröffentlicht: (2025)

Editorial: Carvedilol Remains the First‐Line Treatment of Portal Hypertension After the CALIBRE Trial
von: Thomas Reiberger, et al.
Veröffentlicht: (2025)

Editorial: Combination Therapies for MASH : A Step Forward or More Complexity? Authors' Reply
von: Eric Lawitz, et al.
Veröffentlicht: (2025)

Letter on: ‘Impact of Frailty on the Prognosis of Patients With Liver Cirrhosis Undergoing Insertion of a TIPS ’. Authors' Reply
von: Christian Labenz, et al.
Veröffentlicht: (2026)

Patient Plasma‐Induced Neutrophil Dysfunction Is Associated With Infection Risk and Mortality in Patients With Acute Decompensation of Cirrhosis
von: Supachaya Sriphoosanaphan, et al.
Veröffentlicht: (2025)

Letter: Statins for Cirrhosis: Are we Ready to Move From Cardiovascular Prophylaxis to Portal Pressure Management? Authors' Reply
von: Bernardo de Faria Moraes, et al.
Veröffentlicht: (2026)

Letter: Disease Stage and Absolute Risk in Evaluating the Branched‐Chain Amino Acid to Tyrosine Ratio in Cirrhosis. Authors' Reply
von: Takao Miwa, et al.
Veröffentlicht: (2026)

Letter: Comparing the Efficacy of Adjuvant PD–1 Inhibitor After Curative Resection for Metabolic Dysfunction‐Associated Steatotic Liver Disease Related HCC Versus Other Aetiologies—Authors' Reply
von: Isabella Lurje, et al.
Veröffentlicht: (2025)

Editorial: Recompensation in PBC is good. But is it good enough? Authors' reply
von: Benedikt Silvester Hofer, et al.
Veröffentlicht: (2024)

Predicting Hepatic Decompensation in Patients With Metabolic Dysfunction Associated Steatotic Liver Disease‐Related Cirrhosis: The ABID‐LSM Model
von: Luis Calzadilla Bertot, et al.
Veröffentlicht: (2025)

Editorial: Getting to the Heart of the Matter in IBD—Authors' Reply
von: Ramin Ebrahimi, et al.
Veröffentlicht: (2025)

Serum Villin‐1—A Novel Marker of Gut Barrier Damage in Acutely Decompensated Cirrhosis: A Cohort Study and Validation
von: David Tornai, et al.
Veröffentlicht: (2025)

Editorial: Association of Antibiotic Exposure With Microscopic Colitis—Authors' Reply
von: Máté Szilcz, et al.
Veröffentlicht: (2025)

Editorial: Allostatic Load and Inflammatory Bowel Disease. Authors' Reply
von: Jianhui Zhao, et al.
Veröffentlicht: (2024)

Editorial: To Stop or Not to Stop, Is It Still a Question? Authors' Reply
von: Jeongkuk Seo, et al.
Veröffentlicht: (2024)

Editorial: Predicting Hepatocellular Cancer in Clinical Practice. Authors' Reply
von: Shuaibing Ying, et al.
Veröffentlicht: (2026)

Editorial: Intestinal Ultrasound for the Assessment of Constipation—Out of the Shadows? Authors' Reply
von: Ryan M. Mathias, et al.
Veröffentlicht: (2025)

Letter: Allostatic Load and Adverse Prognosis in Inflammatory Bowel Disease—Need More Evidence. Authors' Reply
von: Jianhui Zhao, et al.
Veröffentlicht: (2024)

Editorial: Cephalosporin‐Induced Liver Injury—Interesting but Tricky. Authors' Reply
von: Raj Vuppalanchi, et al.
Veröffentlicht: (2025)

Editorial: Can We Prevent Inflammatory Bowel Disease? Authors' Reply
von: Fai Fai Ho, et al.
Veröffentlicht: (2025)

Editorial: The Hidden Burden—Stigmatisation in Inflammatory Bowel Disease: Authors' Reply
von: Suprabhat Giri, et al.
Veröffentlicht: (2025)